. 2006 Oct 17;98(1):11–18. doi: 10.1111/j.1349-7006.2006.00350.x

Table 1.

Clinical studies in advanced gastric cancer

Regimen	Reference	Patient	Case no.	Target metastasis	Effect	Survival	Side‐effect (grade 3 or 4)
FAM	MacDonald et al. ⁽ ²⁹ ⁾	Patients with measurable cancer	62	AM, H, N, bone	PR:42%	MST: 5.5 months responder: 12.5 months non‐responder: 3.5 months	Bone marrow: 7/62
FAMTX	Wils et al. ⁽ ³⁰ ⁾	Advanced gastric cancer with or without measurable disease Randomized clinical trial: FAMTX versus FAM	105	PT, H, N, P	PR:41% (FAM 9%)	1‐year survival: 41% 2 years survival 9% Survival was significantly better than FAM	Nausea: 63% Mucositis: 51% Diarrhea: 20% Alopecia: 24%
EAP	Wilke et al. ⁽ ²⁷ ⁾	Advanced gastric cancer with or without measurable disease	34	PT, H, N, P	PR + CR:64%	MST 18 months 2 years survival 26%	Bone marrow: 48%
XELOX	Park et al. ⁽ ⁶¹ ⁾	Advanced gastric cancer with or without measurable disease	20	PT, H, N, P	PR(11) + CR(2): 65%	Median progression free survival: 7.5 months	No grade 3 and 4
Gemcitabine + FOLFOX‐4	Correale et al. ⁽ ⁶⁷ ⁾ Chemother	Metastatic gastric cancer	36	H, N, P, ovary, lung	PR(15) + CR(4): 53%	Survival: 11 months	Neuropenia: 3/36 Mucositis: 4/36 Bone marrow: 6.7%
Docetaxel + capecitabine	Kim et al. ⁽ ⁶² ⁾	Untreated metastatic or recurrent gastric cancer	32	PT, H, N, P	PR¹³ + CR(1): 44%	MST: 8.4 month 1 years survival 0%
TS‐1	Osugi et al.⁽ ⁶⁴ ⁾	Advanced gastric cancer with peritoneal dissemination	18	P	Non‐evaluable	MST: 211 days Control MST: 118 days	Bone marrow: 1/18
TS‐1	Yonemura et al. ⁽ ⁵⁸ ⁾	Advanced gastric cancer with positive cytology	35	Cy1/P0	Non‐evaluable	2 years survival 53% Control 2‐year survival 9%	Grade 3 and 4: 0%
Paclitaxel + TS‐1	Kobayashi et al. ⁽ ⁷⁸ ⁾	Advanced gastric cancer Standard gastrectomy of more than a D2 dissection	50 and CY0‐1	T3‐4, N0‐2, P0, H0 M0,	Safe and feasible	Non‐evaluable	PTX: Neuropathy 1/50, leucopenia 1/50, neutropenia 4/50 S‐1: Diarrhea 1/50, neutropenia 3/50, anemia 1/50
Docetaxel + TS‐1	Yoshida et al. ⁽ ⁵⁷ ⁾	Advanced, recurrent gastric cancer	48	H, N, P, remnant, stomach	PR:56%	MST: 14.3 months Median time tumor progression: 7.3 months	Bone marrow: 58% Anorexia: 15%
HIPEC	Yonemura et al. ⁽ ⁴⁰ ⁾	Advanced, recurrent gastric cancer	83	P	PR:39% (17/43)	Complete resection1 and 5 years survival: 61%, 17% Incomplete resection: 1 and 5 years survival: 30%, 2%	Bowel perforation: 3/83 Bone marrow: 2/83
EPIC	Jeung et al. ⁽ ³⁹ ⁾	Advanced gastric cancer with peritoneal dissemination Palliative gastrectomy	49	P	Better than control group	MST: 12 months Median progression free survival: 7 months	Bone marrow: 17/49 Nause vomiting: 10/49
Peritonectomy + hyperthermic i.p. chemotherapy (cisplatin + mitomycin C)	Yonemura et al. ⁽ ⁴⁵ ⁾	Advanced gastric cancer with peritoneal dissemination Aggressive cytoreduction	107	P	Non‐evaluable	MST: 11.5 months 5 years survival: 6.7%	Not described
NIPS	Yonemura et al. ⁽ ⁵ ⁾	Advanced gastric cancer Preoperative chemotherapy Clinical phase I	51	P	Cytology 75%, PR:45%	MST: 18 months, Peritonectomy: 18 months Complete cytoreduction: 20.4 months	Bone marrow: 16% Operative mortality: 4.5%

5‐FU, 5‐fluorouracil; AM, abdominal mass; CR, complete response; EAP, etoposide + doxorubicin + cisplatin; EPIC, early postoperative intraperitoneal chemotherapy (5‐FU + cisplatin); FAM, 5‐FU + doxorubicin + mitomycin C; FAMTX, 5‐FU + doxorubicin + methotrexate; FOLFOX‐4, oxaliplatin + folinic acid + infusional 5‐FU; H, liver metastasis; HIPEC, hyperthermic intraperitoneal perfusion chemotherapy mitomycin C + etoposide + cisplatin; MST, median survival time; N, lymph node metastasis; NIPS, neoadjuvant intraperitoneal–systemic chemotherapy (methotrexate+ 5‐FU, i.v./docetaxel +carboplatin, i.p.); P, peritoneal dissemination; PR, partial response; PT, primary tumor; XELOX, oxaliplatin + capecitabine.